Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Clinical trial NCT06486779 · RECRUITING

Trial details

NCT number: NCT06486779
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Study type: OBSERVATIONAL

Relapsing Multiple Sclerosis (RMS)

Start date: 2024-12-10
Primary completion: 2028-12-30
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.